Results showed that applying the morphological characteristics as preliminary screening markers for the identification of induced tetraploid lines was feasible.
To analyze whether assisted conceptions need adjustments in first-trimester Down syndrome screening and why modifications in screening markers occur.
These 34 STS primer pairs were further used for screening markers specific to individual chromosomes of H. villosa using a complete set of disomic addition lines.
To investigate links between first trimester Down's syndrome screening markers and adverse pregnancy outcomes; preeclampsia (PE), small for gestational age (SGA), preterm delivery (PD) and placental abruption (PA) in spontaneous, chromosomally normal pregnancies.
The purpose of this study was to determine the association between first-trimester trisomy 21 screening markers (free human chorionic gonadotropin-β [hCG], pregnancy-associated plasma protein A [PAPP-A], and nuchal translucency) and adverse pregnancy outcome.
Since current Down Syndrome screening markers are derived from placenta and fetal liver, these tissues were chosen as target.
We anticipate the set will help support further experimental studies for the identification of new Down Syndrome screening markers in maternal blood.
The use of synthetic oligonucleotides for recombination circumvents any cloning steps and provides maximum flexibility for introducing mutations and screening markers.
Because current screening markers are derived from either fetal liver or placental trophoblasts, we reasoned that new biomarkers can primarily be found to be derived from these two tissues.
Nevertheless, this is the largest microbiological investigation to have been reported so far, and the large number of subjects enrolled with known colonoscopy and histopathology characteristics make it very robust and could open the way to new pathophysiologic fields and new screening markers.
Given that most of the identified markers are associated with a small number of biological processes, it becomes likely that these pathways might also harbor other potential DS screening markers that do not meet the criteria used in our approach or for which insufficient data are available.
